Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBIT: 2020-2025

Historic EBIT for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$35.3 million.

  • Janux Therapeutics' EBIT rose 1.65% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.3 million, marking a year-over-year decrease of 67.85%. This contributed to the annual value of -$98.8 million for FY2024, which is 35.45% down from last year.
  • Janux Therapeutics' EBIT amounted to -$35.3 million in Q3 2025, which was up 21.87% from -$45.1 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' EBIT peaked at -$2.3 million during Q1 2021, and registered a low of -$45.1 million during Q2 2025.
  • In the last 3 years, Janux Therapeutics' EBIT had a median value of -$20.7 million in 2023 and averaged -$26.1 million.
  • Per our database at Business Quant, Janux Therapeutics' EBIT tumbled by 768.07% in 2021 and then soared by 33.38% in 2024.
  • Janux Therapeutics' EBIT (Quarterly) stood at -$13.5 million in 2021, then tumbled by 35.40% to -$18.3 million in 2022, then increased by 11.66% to -$16.1 million in 2023, then plummeted by 79.85% to -$29.0 million in 2024, then climbed by 1.65% to -$35.3 million in 2025.
  • Its EBIT stands at -$35.3 million for Q3 2025, versus -$45.1 million for Q2 2025 and -$34.9 million for Q1 2025.